A detailed history of Invesco Ltd. transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 35,894 shares of ADGI stock, worth $118,809. This represents 0.0% of its overall portfolio holdings.

Number of Shares
35,894
Holding current value
$118,809
% of portfolio
0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
N/A
35,894 New
35,894 $118,000
Q1 2023

May 12, 2023

SELL
N/A
-1,204 Reduced 6.66%
16,863 $55,000
Q4 2022

Feb 13, 2023

BUY
$3.08 - $4.05 $6,363 - $8,367
2,066 Added 12.91%
18,067 $59,000
Q2 2022

Aug 15, 2022

BUY
$2.54 - $4.52 $40,642 - $72,324
16,001 New
16,001 $52,000
Q4 2021

Feb 14, 2022

SELL
$6.35 - $47.04 $44,729 - $331,349
-7,044 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$20.88 - $56.08 $147,078 - $395,027
7,044 New
7,044 $298,000

Others Institutions Holding ADGI

About Adagio Therapeutics, Inc.


  • Ticker ADGI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 108,831,000
  • Market Cap $505M
  • Description
  • Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...
More about ADGI
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.